These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21042045)

  • 1. Somatostatin receptor expression in adrenocortical tumors and effect of a new somatostatin analog SOM230 on hormone secretion in vitro and in ex vivo adrenal cells.
    Mariniello B; Finco I; Sartorato P; Patalano A; Iacobone M; Guzzardo V; Fassina A; Mantero F
    J Endocrinol Invest; 2011 Jun; 34(6):e131-8. PubMed ID: 21042045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
    Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
    Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas.
    Batista DL; Zhang X; Gejman R; Ansell PJ; Zhou Y; Johnson SA; Swearingen B; Hedley-Whyte ET; Stratakis CA; Klibanski A
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4482-8. PubMed ID: 16940446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin receptor subtype gene expression in pituitary adenomas.
    Miller GM; Alexander JM; Bikkal HA; Katznelson L; Zervas NT; Klibanski A
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion.
    Murray RD; Kim K; Ren SG; Lewis I; Weckbecker G; Bruns C; Melmed S
    J Clin Endocrinol Metab; 2004 Jun; 89(6):3027-32. PubMed ID: 15181094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.
    Florio T; Thellung S; Corsaro A; Bocca L; Arena S; Pattarozzi A; Villa V; Massa A; Diana F; Schettini D; Barbieri F; Ravetti JL; Spaziante R; Giusti M; Schettini G
    Clin Endocrinol (Oxf); 2003 Jul; 59(1):115-28. PubMed ID: 12807513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
    J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.
    Hofland LJ; van der Hoek J; Feelders R; van Aken MO; van Koetsveld PM; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; de Herder WW; Beckers A; Lamberts SW
    Eur J Endocrinol; 2005 Apr; 152(4):645-54. PubMed ID: 15817922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
    Hofland LJ; van der Hoek J; van Koetsveld PM; de Herder WW; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; Feelders R; van der Lely AJ; Beckers A; Lamberts SW
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1577-85. PubMed ID: 15070915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
    Danila DC; Haidar JN; Zhang X; Katznelson L; Culler MD; Klibanski A
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2976-81. PubMed ID: 11443154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion.
    Zatelli MC; Piccin D; Tagliati F; Ambrosio MR; Margutti A; Padovani R; Scanarini M; Culler MD; degli Uberti EC
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2797-802. PubMed ID: 12788890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
    Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
    Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated expression of luteinizing hormone receptor in aldosterone-producing adenomas.
    Saner-Amigh K; Mayhew BA; Mantero F; Schiavi F; White PC; Rao CV; Rainey WE
    J Clin Endocrinol Metab; 2006 Mar; 91(3):1136-42. PubMed ID: 16332935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.
    Zatelli MC; Piccin D; Vignali C; Tagliati F; Ambrosio MR; Bondanelli M; Cimino V; Bianchi A; Schmid HA; Scanarini M; Pontecorvi A; De Marinis L; Maira G; degli Uberti EC
    Endocr Relat Cancer; 2007 Mar; 14(1):91-102. PubMed ID: 17395978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of somatostatin, dopamine, progesterone and growth hormone receptor mRNA in canine cortisol-secreting adrenocortical tumours.
    Kool MM; Galac S; van der Helm N; Spandauw CG; Kooistra HS; Mol JA
    Vet J; 2015 Oct; 206(1):108-10. PubMed ID: 26143682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro.
    Zatelli MC; Piccin D; Bottoni A; Ambrosio MR; Margutti A; Padovani R; Scanarini M; Taylor JE; Culler MD; Cavazzini L; degli Uberti EC
    J Clin Endocrinol Metab; 2004 Oct; 89(10):5181-8. PubMed ID: 15472224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple endocrine neoplasia type 1 gene expression is normal in sporadic adrenocortical tumors.
    Zwermann O; Beuschlein F; Mora P; Weber G; Allolio B; Reincke M
    Eur J Endocrinol; 2000 Jun; 142(6):689-95. PubMed ID: 10822234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.
    Vieria Neto L; Wildemberg LE; Colli LM; Kasuki L; Marques NV; Moraes AB; Gasparetto EL; Takiya CM; Castro M; Gadelha MR
    PLoS One; 2013; 8(10):e77406. PubMed ID: 24098585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary.
    Lee M; Lupp A; Mendoza N; Martin N; Beschorner R; Honegger J; Schlegel J; Shively T; Pulz E; Schulz S; Roncaroli F; Pellegata NS
    Endocr Relat Cancer; 2015 Feb; 22(1):111-9. PubMed ID: 25515731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies.
    Saveanu A; Morange-Ramos I; Gunz G; Dufour H; Enjalbert A; Jaquet P
    Eur J Endocrinol; 2001 Jul; 145(1):35-41. PubMed ID: 11415850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.